Compare Novartis AG (NVS) vs SpaceX (SPCX) Price & Performance

Novartis AGTrade

SpaceXTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs SpaceX — how do they compare? Novartis AG trades at $139.89 (market cap $262.64B), while SpaceX trades at $146.94 (market cap $2.02T). The key difference: SpaceX is far larger — about 7.7× Novartis AG's market cap, and Novartis AG pays a 3.44% dividend while SpaceX pays none. Which is the better fit depends on your goals.

	NVS	SPCX
Market Cap	$262.64B	$2.02T
Sector	Health	Technology
52-Week High	$168.62	$202.09
52-Week Low	$121.80	$108.27
Enterprise Value	$303.97B	$1.96T
Dividend Yield	3.44%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

SpaceX

SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.

The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis shares plunge 12.5% after two Phase 3 drug trials fail primary goalsPRNewsWire · 18 hours agoBearish Amgen shares drop 10% after Novartis fails cholesterol drug trial, despite Amgen's own cancer trial success.24/7 Wall Street · 1 day agoBearish Novartis shares drop 10% after del-desiran fails Phase 3 trial for myotonic dystrophyProactive Investors · 1 day agoBearish View details →

SPCX

AI-driven IPO surge in 2026 echoes 1999 Internet Boom with high valuations despite lossesSeeking Alpha · 18 hours agoBearish SpaceX shares drop 5% as $47.2B insider share unlock hits market, dragging space sector down.24/7 Wall Street · 19 hours agoBearish Anthropic researcher warns AI has >10% chance to kill all humans within a decade amid safety concerns.CNBC · 1 day agoBearish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.